Igm Biosciences Stock Today
| IGMS Stock | USD 1.21 0.02 1.63% |
PerformanceVery Weak
| Odds Of DistressVery High
|
IGM Biosciences is selling for under 1.21 as of the 19th of March 2025; that is 1.63 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.18. IGM Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of September 2019 | Category Healthcare | Classification Health Care |
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. The company has 34.39 M outstanding shares of which 1.07 M shares are currently shorted by private and institutional investors with about 4.14 trading days to cover. More on IGM Biosciences
Moving together with IGM Stock
| 0.7 | VANI | Vivani Medical Earnings Call This Week | PairCorr |
Moving against IGM Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
IGM Stock Highlights
| President CEO | Fred JD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIGM Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand IGM Biosciences' financial leverage. It provides some insight into what part of IGM Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IGM Biosciences (IGMS) is traded on NASDAQ Exchange in USA. It is located in 325 East Middlefield Road, Mountain View, CA, United States, 94043 and employs 149 people. IGM Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 73.52 M. IGM Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 34.39 M outstanding shares of which 1.07 M shares are currently shorted by private and institutional investors with about 4.14 trading days to cover.
IGM Biosciences currently holds about 469.14 M in cash with (153 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check IGM Biosciences Probability Of Bankruptcy
Ownership AllocationIGM Biosciences has a total of 34.39 Million outstanding shares. Over half of IGM Biosciences' outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check IGM Ownership Details
IGM Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-12-31 | 193 K | |
| Td Asset Management Inc | 2024-12-31 | 164.5 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 157.8 K | |
| Rhenman Partners Asset Management Ab | 2024-12-31 | 126.1 K | |
| Two Sigma Investments Llc | 2024-12-31 | 107.6 K | |
| Wellington Management Company Llp | 2024-12-31 | 101.1 K | |
| Bruce & Co Inc | 2024-12-31 | 100 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 96.9 K | |
| Gsa Capital Partners Llp | 2024-12-31 | 93.5 K | |
| Baker Bros Advisors Lp | 2024-12-31 | 4.1 M | |
| T. Rowe Price Associates, Inc. | 2024-12-31 | 3.6 M |
IGM Biosciences Historical Income Statement
IGM Stock Against Markets
IGM Biosciences Corporate Management
| TS Harigopal | Senior Operations | Profile | |
| Faraz Siddiqui | Senior Operations | Profile | |
| Angus Sinclair | Senior ImmunoOncology | Profile | |
| Elizabeth JD | Senior Property | Profile | |
| Elaine Sapinoso | Senior Quality | Profile | |
| Misbah CPA | Chief Officer | Profile | |
| Lisa Decker | Chief Officer | Profile |
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.